Immunocompetence in non-seminomatous testicular cancer patients before any treatment and one year after completion of therapy

Anticancer Research

Volumn 24, Issue 5 B, 2004, Pages 3251-3255

  Kaštelan, Željko ^a   Pasini, Josip ^a   Derežić, Danijel ^a   Lukač, Josip ^b   Kusić, Zvonko ^b   Mrazovac, Danijel ^a   Šošić, Hrvoje ^a   Kaštelan, Maja ^b  

^a KBC Zagreb   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Immunocompetence; Non seminomatous testicular cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; MITOGENIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOTOXICITY; HUMAN; IMMUNOCOMPETENCE; LYMPHOCYTE SUBPOPULATION; MALE; MONOCYTE; NEUTROPHIL; NON SEMINOMATOUS TESTICULAR CANCER; PRIORITY JOURNAL; TESTIS CANCER;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; ETOPOSIDE; HUMANS; IMMUNOCOMPETENCE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MALE; ORCHIECTOMY; SEMINOMA; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TESTICULAR NEOPLASMS;

EID: 6344291381     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Catalona WJ, Smolev JK and Harty JI: Prognostic value of host immunocompetence in urologic cancer patients. J Urol 114: 922-926, 1975.
2. Decenzo JM, Allison R and Leadbetter GW: Skin testing in genitourinary carcinoma: 2-year follow-up. J Urol 114: 271-273, 1975.
3. Nielsen H and Rorth M: Phagocytosis and killing of Candida albicans by blood monocytes from patients with non-seminomatous testicular carcinoma: effect of chemotherapy. Acta Pathol Microbiol Immunol Scard 93: 85-89, 1985.
4. Nielsen H, Rorth M and Bennedsen J: Monocyte chemotaxis in patients with nonseminomatous testicular carcinoma. Effect of chemotherapy. Cancer Immunol Immunother 19: 68-71, 1985.
5. Trulson A, Nilsson S and Venge P: Monocyte activation in patients with non-seminomatous germ cell tumor of the testis before and after tumor eradication. J Clin Pathol 49: 381-385, 1996.
6. Krainer M, Wolf HM, Wiltschke C et al: Transient increase in mitogen-induced lymphoproliferative responses in patients with testicular cancer after BEP chemotherapy. Urology 55: 934-938, 2000.
7. Kaštelan M, Kovačić K, Tarle R et al: Analysis of NK cell activity, lymphocyte reactivity to mitogens and serotest PSA and TPS in patients with primary and disseminated prostate cancer, PIN and BPH. Anticancer Res 17: 1671-1676, 1997.
8. Lukač J, Kusić Z, Kovačević D et al: Neutrophil and monocyte functions in patients with colorectal adenocarcinoma during fluorouracil therapy. Anticancer Res 15: 2805-2810, 1995.
9. Richie JP: Neoplasms of the testis. In: Campbell's Urology, ed 6 (Walsh PC, Retik AB, Stamey TA et al, eds). Philadelphia, WB Saunders, 1992, pp 1222-1263.
10. Boring CC, Squires TS, Tong T and Montgomery S: Cancer statistics. Cancer J Clin 44: 7-26, 1994.
11. Pillai MR, Balarm P, Padmanabham TK et al: Immunocompetence in lung cancer. Cancer 64: 1853-1858, 1989.
12. Tarle M, Kraljić I and Kaštelan M: Comparison between NK cell activity and prostate cancer stage and grade in untreated patients: correlation with tumor markers and hormonal serotest data. Urol Res 21: 17-21, 1993.
13. Wiltschke C, Krainer M, Budinsky AC et al: Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study. Br J Cancer 71: 1292-1296, 1995.
14. Soygur T, Beduk Y, Yaman O et al: Analysis of the peripheral blood lymphocyte subsets in patients with bladder carcinoma. Urology 53: 88-91, 1999.
15. Krainer M, Wolf H, Michl I et al: Natural killer cell activity in long-term survivors of testicular cancer. Influence of cytostatic therapy and initial stage of disease. Cancer 75: 539-544, 1995.
16. Kubota Y, Ohji H, Itoh K, Sasagawa I and Nakada T: Changes in cellular immunity during chemotherapy for testicular cancer. Int J Urol 8: 604-608, 2001.
17. Belldergrun A, Muul LM and Rosenberg SA: Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cell cancer - isolation, characterization, and antitumor activity. Cancer Res 48: 206-214, 1988.
18. Heo DS, Whiteside TL, Kanbour A and Herberman RB: Lymphocytes infiltrating human ovarian tumors. Role of leu-19 (NKH1)-positive recombinant ovarian tumors. J Immunol 140: 4042-4049, 1988.
19. Allen CA and Hogg N: Association of colorectal tumor epithelium expression HLA-D/DR with CD8-positive T cells and mononuclear phagocytes. Cancer Res 47: 2919-2923, 1987.
20. Marx JL: Natural killer cells help defend the body. Science 210: 624-626, 1980.
21. Nair MPN and Schwartz SA: Suppression of natural killer activity and antibody-dependent cellular cytotoxicity by cultured human lymphocytes. J Immunol 126: 221-226, 1981.
22. Marumo K, Ikeuchi K, Baba S, Ueno M and Tazaki H: Natural killer cell activity and recycling capacity of natural killer cells in patients with carcinoma of the prostate. Keio J Med 38: 27-35, 1989.
23. Brunda MJ, Herberman RB and Holden HT: Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 124: 2682-2687, 1980.
24. Kaštelan M, Kraljid I and Tarle M: NK cell activity in treated prostate cancer patients as a probe for circulating tumor cells: hormonal regulatory effects in vivo. Prostate 21: 111-120, 1992.